Stoke Therapeutics, Inc. (NASDAQ:STOK) Insider Barry Ticho Sells 10,000 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $12.07, for a total value of $120,700.00. Following the sale, the insider now directly owns 51,277 shares of the company’s stock, valued at approximately $618,913.39. This represents a 16.32 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Stoke Therapeutics Trading Down 5.3 %

NASDAQ:STOK opened at $11.43 on Wednesday. The firm has a market capitalization of $605.45 million, a price-to-earnings ratio of -5.44 and a beta of 0.95. Stoke Therapeutics, Inc. has a 1-year low of $3.78 and a 1-year high of $17.58. The business’s fifty day moving average price is $12.39 and its 200 day moving average price is $13.75.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. Equities analysts forecast that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. Leerink Partners assumed coverage on Stoke Therapeutics in a report on Monday, October 14th. They set an “outperform” rating and a $18.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Stoke Therapeutics presently has a consensus rating of “Buy” and an average target price of $20.83.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Assenagon Asset Management S.A. acquired a new position in Stoke Therapeutics in the 2nd quarter worth about $19,835,000. SG Americas Securities LLC increased its holdings in shares of Stoke Therapeutics by 610.3% during the 2nd quarter. SG Americas Securities LLC now owns 68,601 shares of the company’s stock valued at $927,000 after acquiring an additional 58,943 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Stoke Therapeutics by 4.1% during the 1st quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company’s stock valued at $23,160,000 after acquiring an additional 67,052 shares during the last quarter. Los Angeles Capital Management LLC increased its holdings in shares of Stoke Therapeutics by 54.3% during the 3rd quarter. Los Angeles Capital Management LLC now owns 103,005 shares of the company’s stock valued at $1,266,000 after acquiring an additional 36,240 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its holdings in shares of Stoke Therapeutics by 426.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock valued at $18,741,000 after acquiring an additional 1,123,500 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.